Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivatives, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## group, in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, --CH.sub.2 OR.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.

Abstract: An agent for inhibiting the binding of 5.alpha.-dihydrotestosterone with androgen receptor, which comprises at least one extract from herbs or one of specific xanthone compounds, and a process for obtaining the agent.

Abstract: A cloned single-strand DNA comprising nucleotide sequence which encodes human motilin precursor, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a fragment of the single- or double-strand DNA, a plasmid, in which the double-strand DNA or its fragment is integrated, as well as a process for the preparation of the single- or double-strand DNA.

Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.

Abstract: 7a-Nitromethyl-2,3,5,6,7,7a-hexahydro-1H-pyrrolizine of the formula ##STR1## and salts thereof, as well as processes for the preparation of the compound and 7a-aminomethyl-2,3,5,6,7,7a-hexahydro-1H-pyrrolizine and salts thereof.

Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.

Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## group, in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, --CH.sub.2 OR.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.

Abstract: A percutaneous-administration-type pharmaceutical preparation of nitroglycerin comprising a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is disposed on one surface of the backing, wherein the pressure-sensitive adhesive layer contains alkyl (meth)acrylate copolymer in the concentration of 80-95% by weight and the nitroglycerin in the concentration of 5-20% by weight, said copolymer contains as major copolymer components alkyl (meth)acrylate with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexylmethacrylate in the concentration of 40-90% by weight based on the total weight of said alkyl (meth)acrylates, and the copolymer has a rolling ball tack value of 2 or less. The preparation obtained makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for long periods of time.

Abstract: The invention is a liquid food for supplying protein principally containing protein, seasonings, flavoring materials and water, wherein it contains 5 to 15% by weight of lactalbumin as the protein. The lactalbumin is obtained by heating to denature under conditions so as to form a cloudy solution. The food is useful for undernourished patients who suffer from hypoproteinemia, hypoalbuminemia or common healthy men who need protein so as to desire to supply nutritious food and develop their muscles.

Abstract: Remedies, preventives and functional diets for diabetic diseases, esp., diabetes, contain phytic acid or its salt or salts. The salt of phytic acid is a non-toxious metal salt, or a non-toxious salt with an organic base, a basic amino acid or an organic ester residue, and has a compositional form together with or separately from phytic acid.

Abstract: 1-Pyrrolidineacetamide derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen atom or a trialkylsilyl group, R.sub.2 and R.sub.3 are hydrogen atom, respectively, when R.sub.1 is hydrogen atom, R.sub.4 is an alkyl group, R.sub.5 is a radical of ##STR2## in which R.sub.6 and R.sub.7 are an alkyl group, respectively, m and n are an integer of 1 to 3, respectively,or R.sub.4 represents together with R.sub.5 a hetero cyclic ring having nitrogen and silicon atoms or piperazine ring having a substituent of ##STR3## in which R.sub.6 and n have the meanings as referred to, and R.sub.2 and R.sub.4 as well as R.sub.3 and R.sub.5 form a hetero cyclic ring, respectively, connected with an alkylene chain, where R.sub.1 is the trialkylsilyl group, salts thereof, a process for the preparation thereof, as well as use thereof as for a medicine.

Abstract: The present invention relates to intermediates for synthesizing BH.sub.4 and derivatives thereof. The intermediates are shown as follows: ##STR1## wherein R.sub.1 is a hydrogen atom, alkyl, aralkyl, or aryl group; R.sub.2 is an alkyl, hydroxyalkyl, or polyhydroxyalkyl group; R.sub.3 and R.sub.4 are the same or different and represent alkyl, aralkyl, or aryl group; R.sub.5, R.sub.6, R.sub.7, and R.sub.8 are the same or different and represent a hydrogen atom or acyl group; R.sub.9 is an alkyl, aralkyl, or aryl group; R.sub.10 and R.sub.11 are the same or different and represent a hydrogen atom or acyl group; n is an integer of 5 or less; and HX is an acid. The invention also relates to a process for the preparation of L-biopterin.

Abstract: Preventives or remedies for medicinal and alcoholic poisoning contain as a pharmaceutically effective component phytic acid or its salt which may be an innoxious metal salt, or an innoxious salt with an organic base, a basic amino acid or an organic ester residue.

Abstract: A pharmaceutical composition comprising as an effective ingredient, a pyrazole compound of the formula ##STR1## wherein each of R.sub.1 and R.sub.2 is phenyl or p-halogenophenyl radical, respectively, and R.sub.3 is hydrogen atom or methyl radical,or a salt thereof. The composition is used for curing immunity diseases and a nephropathy.

Abstract: Some of antineoplastic agents, for instance, adriamycin and daunorubicin, have a positive charge at physiological pH. Such drugs possess high affinity for binding to steroidal sulfate by means of electrostatic force. The invention utilizes this property to prepare steroidal sulfate liposomes having a net negative charge and encapsulating the antineoplastic agent.

Abstract: A process for the preparation of pyrrolizine derivatives of the formula ##STR1## wherein R is --CN or --CH.sub.2 NH.sub.2, and salts thereof.

Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition.

Abstract: A glycyrrhetic acid derivative of the formula ##STR1## wherein X and Y are hydrogen atom, respectively or X is oxygen atom together with Y, A.sub.1 is methylene or carbonyl radical, A.sub.2 is hydrogen atom, cyano, carbamoyl, carboxyl radical or alkoxycarbonyl group, m and n are an integer, respectively, R.sub.1 is a radical of ##STR2## in which R.sub.2 is an alkyl, alkenyl group, phenyl radical or a substituted phenyl radical, A.sub.3 is S, O or NH, and l is an integer, a process for the preparation of the derivatives, and use of the derivative as a pharmaceutical agent.

Abstract: A removable rating plug for a circuit breaker provides an active variable impedance in series with a reference resistor between the sensing terminals of the circuit breaker trip circuit to adjust the sensing voltage produced in response to the input current received from current monitors in the protected circuit. The active variable impedance, which is energized by the input current, includes a high gain transistor amplifier, preferably a Darlington transistor, controlled by an operational amplifier. A control circuit includes a pair of reference diodes which match the forward drop across the Darlington transistor when full on, in series with a reference voltage selection circuit which applies a reference voltage to the non-inverting input of the operational amplifier.

Abstract: An organo-silicone compound of the formula ##STR1## wherein X is a methylene or carbonyl radical, Y is an NH or O, n is an integer, R.sub.1 is a hydrogen atom, halogen atom or alkyl group, R.sub.2, R.sub.3 and R.sub.4 are an alkyl group, alkoxy group, phenyl radical or substituted phenyl radical, respectively, and R.sub.5 is a hydrogen atom or a group of ##STR2## in which X, Y, n, R.sub.2, R.sub.3 and R.sub.4 have the meanings as referred to, and used as an anti-tumor agent or for use in anti-tumor compositions.